Please assess the completion status of the following clinical trial:

Trial Title: An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Relapsed/refractory diffuse large B cell lymphoma (DLBCL), relapsed/refractory peripheral T cell lymphoma (PTCL) (all subtypes excluding anaplastic large cell lymphoma), relapsed/refractory Cutaneous T cell lymphoma (CTCL) mycosis fungoides/sezary syndrome (MF/SS), relapsed/refractory primary mediastinal B lymphoma (PMBL), and relapsed/refractory mediastinal gray zone lymphoma (MGZL)~* Expression of CD30~* Subjects must be 18 years or older (≥ 15 years for PMBL)~Exclusion Criteria:~* Known central nervous system (CNS) lymphomas; Active cerebral/meningeal disease related to the underlying malignancy~* Active, known, or suspected autoimmune disease

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nivolumab+Brentuximab Vedotin (Type: EXPERIMENTAL): Nivolumab+Brentuximab Vedotin dose as specified

Based on this trial design, predict the completion outcome and termination type (if applicable).